Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Swiss Cancer Registry on Safety and Efficacy of 177Lu-ITG-PSMA-1 Radionuclide Therapy in Prostate Cancer Patients

NCT06830408 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT06830408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06830408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Swiss Cancer Registry on Safety and Efficacy of 177Lu-ITG-PSMA-1 Radionuclide Therapy in Prostate Cancer Patients
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Observational
Overall status
Completed
Start date
July 6, 2020
Completion date
January 13, 2025
Enrollment
250 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc